Marianne's brings its Regenerative Organic Certified® and Organic Avocado Oils to Target, the only Seed Oil Free Certified® avocado oils on shelves

SACRAMENTO, Calif., Oct. 6, 2026/PRNewswire/ -- Marianne's, the premium pantry brand UC Davis used at the benchmark for 100% purity, is bringing its most rigorously verified oils to one of America's biggest retailers. The brand's Regenerative Organic Certified® (ROC®) Avocado Oil and Organic Avocado Oil are now rolling into more than 800 Target stores nationwide this fall. The launch marks another milestone in Marianne's fast national climb, coming less than a year after its launch into broader retail.

The timing is no accident. A category once taken at face value is now under a microscope: a recent 2026 UC Davis research study found that the majority of products labeled "made with 100% pure avocado oil" were actually adulterated with cheaper oils. Marianne's was named the benchmark for purity in the 2026 study, and it was the oil that every other brand was measured against. That verified purity is exactly what the Target shopper is looking for on the shelf.

Both Regenerative Organic Certified® Avocado Oil and Organic Avocado Oil certifications mean something specific, and Marianne's holds itself to the highest standards. Organic certification requires that avocados are grown without synthetic pesticides or fertilizers. Regenerative Organic Certified® goes further, building on that organic foundation with the highest standards in farming today: rebuilding soil health, protecting biodiversity, and ensuring fair treatment and livelihoods for the people who grow the crop. It is one of the most rigorous, independently verified standards a food product can carry.

For Marianne's, those standards are backed by proof, not just labels. Every load of oil brought in from trusted farmers is third-party tested for purity against all three CODEX markers - fatty acid profile, sterols and tocopherols and is the only Seed Oil Free Certified® avocado oil on shelves, so what the bottle claims is exactly what is inside. With a neutral flavor and a smoke point up to 500°F, they are built for everything from high-heat searing and roasting to baking and everyday cooking.

That commitment starts at the source. Marianne's follows the avocado harvest around the world throughout the year to ensure the freshest possible oil, and its Regenerative Organic Certified® avocados are processed at a women-led facility in East Africa.

"What's in the bottle should be exactly what's on the label. That sounds simple, but in this category it's rare," said Marianne Adams, namesake of Marianne's. "When independent scientists use your oil as the definition of pure, it proves we mean it. Bringing our Regenerative Organic Certified® and Organic Avocado Oils to Target puts that proven purity within reach of families across the country, and gives shoppers an avocado oil they can finally trust."

The expansion reflects Target's continued investment in emerging food brands that pair premium quality with ingredient transparency. Marianne's was selected for the retailer's Takeoff program, which spotlights high-growth emerging brands, reinforcing its position among a new generation of pantry staples raising the standard on everyday shelves.

The Target rollout builds on a fast-expanding retail footprint that includes Amazon, Sprouts, H-E-B, Fresh Thyme, Hy-Vee, Erewhon, Costco, and regional grocers nationwide. Rooted in five generations of family ingredient expertise, Marianne's continues to deliver cooking oils that are responsibly sourced, rigorously tested, and made without compromise.

For more information, visit www.mariannesharvest.com or follow @mariannesharvest on Instagram.

SOURCE Marianne's Harvest

Share this article

The redesigned website and newly renovated office highlight three decades of comprehensive, family-focused dental care in Oceanside, N.Y.

OCEANSIDE, N.Y., Oct. 6, 2026 /PRNewswire/ -- All About Smiles Dentistry, a multispecialty dental practice serving Oceanside and the surrounding Long Island communities since 1996, has launched a redesigned website and completed renovations to its office at 3471 Long Beach Road.

The updated website at allaboutsmilesoceanside.com introduces a refreshed design that makes it easier for families to explore the practice's comprehensive range of services, meet its team of three specialized doctors, and access patient resources. The site reflects the practice's longstanding commitment to clear communication and genuine connection with the Oceanside community.

Founded by Dr. Pamela L. Sands, DDS, All About Smiles Dentistry has built a reputation over more than three decades as a one-of-a-kind dental home where patients of all ages receive personalized, family-focused care. Dr. Sands earned her Doctor of Dental Surgery from the State University of New York at Stony Brook and completed her specialty certificate in pediatric dentistry at Montefiore Medical Center/Albert Einstein College of Medicine, where she was elected Chief Resident. With extensive experience in pediatric dentistry and specialized training in the care of patients with developmental and physical disabilities, Dr. Sands has dedicated her career to creating a warm, nurturing environment for children and families.

The office renovation complements the website redesign by enhancing the in-person patient experience. The updated space reflects the practice's emphasis on comfort, modern technology, and a welcoming atmosphere. The practice operates as a fully digital office equipped with the iTero Lumina™ scanner, which features advanced near-infrared imaging (NIRI) technology as a radiation-free diagnostic alternative to traditional digital radiography.

"I am so proud of the journey All About Smiles has taken over the past 30 years, and this new chapter is incredibly exciting for our entire team," says Dr. Pamela L. Sands, DDS, founder of All About Smiles Dentistry. "Our new website and renovated office represent our continued commitment to providing exceptional, compassionate care for every member of the family. We have always believed that guests become friends and friends become family, and we want that feeling to come through from the moment someone visits our site to the moment they walk through our doors."

The practice's collaborative, multispecialty team also includes Dr. Christine Collins, DDS, who focuses on general, cosmetic, and implant dentistry. Dr. Collins earned her DDS from the State University of New York at Stony Brook and completed a General Practice Residency at Northshore University Medical Center. She is currently pursuing a comprehensive dental implantology curriculum through New York University and the American Academy of Implant Dentistry.

Board-certified orthodontist Dr. Navinder Nat, DDS, brings specialized expertise in orthodontics and dentofacial orthopedics. Dr. Nat earned her DDS from the University at Buffalo School of Dental Medicine and completed her orthodontic certification at St. Barnabas Hospital. Her treatment approach encompasses airway-focused orthodontics, TMJ therapy, and holistic treatment planning for children, teens, and adults.

All About Smiles Dentistry provides a comprehensive range of dental services, including:

- Pediatric Dentistry

- Special Needs Pediatric Dentistry

- Orthodontics (Invisalign®, Braces, Clear Aligners)

- Cosmetic Dentistry

- Restorative Dentistry

- Wellness and Biomimetic Dentistry

- Preventive Dentistry

- Sedation Dentistry

- Emergency Dentistry

- Digital Dentistry

About All About Smiles Dentistry

All About Smiles Dentistry is a multispecialty dental practice offering comprehensive care for patients of all ages in Oceanside, N.Y. Founded in 1996 by Dr. Pamela L. Sands, DDS, the practice specializes in pediatric, general, cosmetic, restorative, and orthodontic dentistry with a focus on wellness-centered, family-focused care. Prospective patients can learn more about All About Smiles Dentistry by visiting https://www.allaboutsmilesoceanside.com or by calling the office at 516-536-5800. The practice is located at 3471 Long Beach Rd, Oceanside, NY 11572.

SOURCE All About Smiles Dentistry

Share this article

Vermiculus Launches AI-Powered, Configurable Corporate Action System

VeriAct, Vermiculus corporate action system, enables market infrastructures to manage any corporate action event type through a fully configurable, cloud-native system with complete transparency, automation, and scalability.

STOCKHOLM, Oct. 6, 2026 /PRNewswire/ -- Vermiculus, a global independent provider of market infrastructure technology, today announced the launch of VeriAct corporate action system, a cloud-native solution designed to handle the full lifecycle of corporate action processing.

The corporate action system features fully configurable event types, formulas, and tax rules, allowing organizations to respond quickly to new market demands. Explicit and auditable outcome logic provides complete transparency and traceability throughout the processing chain, while comprehensive notification capabilities keep market participants informed throughout the event lifecycle.

The system is designed to handle both official processing and simulations with equal precision, making it suitable for any system that depends on corporate action results. It efficiently processes complex scenarios by parameterizing any event type invented in the market, while ensuring accurate outcomes and consistent delivery to downstream systems.

"Corporate actions require market infrastructures to manage a constantly evolving range of event types. With our new AI-powered corporate action system, we've made that process dramatically simpler and more flexible," said Gustav Nystedt, Senior Product Expert at Vermiculus. "With this launch, we are providing market infrastructures with a flexible product built for change that can manage any event types, regulatory requirements, and local market practices without lengthy hard-code projects."

The VeriAct corporate action system is used by clients such as B3, one of the world's largest market infrastructure operators, Built on a microservices architecture, the system offers flexible deployment options and seamless interoperability through message-based integration. Individual components can operate independently, enabling high-performance processing while isolating workloads and simplifying integration with existing market infrastructure environments.

The VeriAct corporate action system is available as a stand-alone solution or as part of Vermiculus' broader portfolio of cloud-native systems supporting trading, clearing, and CSD operations.

About Vermiculus

Vermiculus Financial Technology AB provides best-in-class trading, clearing, and CSD solutions to market participants around the world. Vermiculus' solutions are the first to bring state-of-the-art advances in dynamic microservice architecture together with vast experience in clearing house, exchange, and CSD business requirements

The company started its operation in 2020 and is founded by industry experts with the incentive to revolutionize the technology of exchanges, clearing houses, and CSDs. With its headquarters in Stockholm, Sweden, Vermiculus consists of hand-picked teams, trained to deliver mission-critical solutions. Learn more at vermiculus.se

For further information, please contact:

Amelie Hedenstierna - PR & Communications 

Vermiculus Financial Technology

Tel +46-(0)73 622 24 54

[email protected]

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

SOURCE VermiculusFT

Share this article

Betsson Group: Odds Favourites for the 2026 Nobel Prize in Literature

TA'XBIEX, Malta, Oct. 6, 2026 /PRNewswire/ -- On Thursday, 8 October, the Nobel Prize in Literature will be announced by the Swedish Academy. At Swedish-founded global betting company Betsson, which has offered odds on the prize for more than a decade, Chinese author Can Xue is currently the favourite, followed by Anne Carson and Gerald Murnane.

This year's list features around 40 authors from across the globe, many of whom have appeared regularly in Nobel discussions over the years. Notably, Asian literature is particularly well represented, with writers such as Can Xue and Amitav Ghosh among the strongest contenders.

Can Xue, widely regarded as China's leading experimental writer, has long been mentioned as a potential Nobel laureate and was the odds favourite in 2023. The author is currently priced at 5.00, followed by Canadian poet Anne Carson at 7.00 and Australian novelist Gerald Murnane at 8.00.

"A recurring pattern is that authors who attract strong support from both literary experts and bettors often remain leading contenders year after year. Can Xue, Anne Carson and Gerald Murnane all fit that pattern. More commercially prominent literary stars, by contrast, can generate significant buzz and climb into the top five, only to fall back in the rankings the following year," said Robin Olenius, Head of PR at Betsson.

In recent years, Nobel winners have often been found among Betsson's leading candidates. Last year's winner, László Krasznahorkai, had the second-lowest odds before the announcement. Jon Fosse was also ranked second among the favourites before receiving the prize, while Annie Ernaux was the third favourite in the year she won. Louise Glück was likewise among the leading contenders before winning in 2020.

"As Betsson has become increasingly international, we are seeing betting activity and literary interest from a broader range of markets around the world compared with earlier years," said Robin Olenius, Head of PR at Betsson.

However, the Nobel Prize also has a history of producing surprises. Bob Dylan and Han Kang were not among the top favourites, while perhaps the biggest surprise in recent years was Abdulrazak Gurnah, who was not even included in the betting market.

Betsson: Odds Nobel prize in literature 2026

https://www.betsson.com/en/sportsbook/specials/specials/nobel-prizes?tab=outrights 

Can Xue                           5

Anne Carson                    7

Gerald Murnane               8

Amitav Ghosh                  9

César Aira                        9

Cristina Rivera Garza     11

Thomas Pynchon           13

Jamaica Kincaid             13

Alexis Wright                  13

Michel Houellebecq       15

Mircea Cartarescu         15

Haruki Murakami            19

Salman Rushdie             19

Enrique Vila-Matas         19

Pierre Michon                 21

Carl Frode Tiller             21

Raul Zurita                     21

Colm Toibin                    21

Benjamin Labatut          21

Margaret Atwood           27

Juan Gabriel Vasquez   27

Gabriela Wiener            27

Mariana Enriquez          27

Ko Un                            29

Karl Ove Knausgard     29

Ersi Sotiropoulos          29

Joyce Carol Oates       32

Helle Helle                   32

Peter Nadas                 32

Milton Hatoum             32

Samanta Schweblin     32

Homero Aridjis             32

Lyudmila Ulitskaya      36

Yoko Tawada               36

Elena Poniatowska      36

Isabel Allende              36

Stephen King               50

Paul Simon                  50

For more information, please contact: 

Robin Olenius, Head of PR, Betsson Group

email: [email protected] 

About Betsson Group

Originally founded in 1963, Betsson Group is a global leader in the entertainment industry, offering multiple services to consumers, including gaming, betting and infotainment. With proprietary technology across its diverse product offering, Betsson serves customers with a B2C offering and other gaming operators as a B2B supplier. The company's vision is to provide the best customer experience in the industry. Sustainability is an integrated part of Betsson's strategy, as taking responsibility for customers, employees and communities is a prerequisite for running a sustainably successful business. 

Betsson Group employs around 3,000 people in Europe, South America, Asia and North America. The parent company, Betsson AB, is listed on Nasdaq Stockholm. Read more on: www.betssongroup.com and www.betssonab.com 

This information was brought to you by Cision http://news.cision.com

Share this article

New Add-On Service Extends ION MXDR Beyond the Enterprise Perimeter to Identify Exposed Credentials, Brand Impersonation, and Emerging Risks Before They Become Security Incidents

ZURICH, Switzerland, Oct. 6, 2026 /PRNewswire/ -- Ontinue, a leading MXDR partner providing nonstop managed security operations through its Agentic SOC, today announced the launch of ION for Dark Web Monitoring (DWM), a new managed add-on service that extends ION MXDR to continuously identify exposed credentials, detect brand impersonation attempts, and uncover emerging external threats before attackers can exploit them.

Compromised credentials are traded across criminal forums, lookalike domains are created to impersonate trusted brands, and sensitive information can surface across deep and dark web sources long before security teams become aware of the exposure. Exposed credentials can show up on the dark web within 24 hours. Yet reports have shown that only 19% of organizations continuously monitor for that exposure and automatically remediate it. Most organizations lack the visibility, expertise, and operational processes needed to identify and respond to these risks before they lead to compromise.

ION for Dark Web Monitoring addresses this challenge by combining continuous monitoring across curated threat intelligence sources with the same investigation, automation, and response capabilities that power Ontinue's managed security operations service. Rather than simply generating alerts, ION for DWM operationalizes external threat intelligence, transforming exposures into investigated incidents and actionable security outcomes.

"The security perimeter no longer ends at the edge of the enterprise," said Moritz Mann, CEO of Ontinue. "Organizations need visibility into the threats that exist beyond their environment, whether that's stolen credentials being offered for sale, new brand impersonation campaigns, or emerging signs of attacker activity. Most dark web monitoring solutions stop at detection. ION for Dark Web Monitoring goes further by investigating findings, assessing risk, and helping customers take action before exposures become incidents."

Turning External Threat Intelligence into Action

ION for Dark Web Monitoring continuously monitors customer-owned domains and brand assets across trusted intelligence sources spanning the clear, deep, and dark web. Findings are validated, enriched, and operationalized through the ION SecOps Platform, enabling customers to leverage the same Cyber Defense Center analysts, automation workflows, and response capabilities already protecting their environments 24/7.

Key capabilities include:

- Continuous Monitoring for Exposed Credentials: ION for DWM continuously identifies credentials associated with customer domains that may have been exposed through breaches, criminal marketplaces, or other external sources, helping organizations reduce the likelihood of account compromise and unauthorized access.

- Detection of Typosquatting and Brand Impersonation: The service detects suspicious domains designed to mimic trusted brands and assesses their potential risk, enabling organizations to identify and disrupt phishing, fraud, and impersonation campaigns earlier.

- Integrated Investigation and Response: Unlike traditional monitoring tools that generate raw alerts, ION for DWM validates findings, assesses relevance and severity, and operationalizes them through ION MXDR workflows. Approved response actions can be executed automatically or with customer oversight based on predefined rules of engagement.

- Unified Security Operations: External exposures flow directly into Microsoft Sentinel and the ION SecOps Platform, where they are investigated alongside other security signals using the same automation, detection, and response processes that support Ontinue's Agentic SOC.

"ION for Dark Web Monitoring expands our visibility beyond our existing tools, giving us better insight into external risks and bringing validated findings into the managed security operations we already trust," said Jason Burzenski, Vice President, Global Head of Cyber Security at Epiq.

A Managed Approach to Reducing Exposure Risk

Many organizations receive threat intelligence feeds and dark web monitoring alerts but lack the resources to investigate findings, determine relevance, or coordinate response actions. As a result, exposures often remain unresolved until attackers take advantage of them.

ION for Dark Web Monitoring was designed to close that gap by providing a managed service experience rather than another security dashboard. Every finding benefits from expert review, contextual analysis, and operational response, helping security teams focus on reducing risk rather than managing alerts.

"Dark web monitoring has moved from a nice-to-have add-on to a meaningful component of a mature MDR program. Adversaries do not operate in isolation from the organizations they target. Credential exposure, ransomware leak staging, and brand impersonation activity on dark web forums often precede or accompany active intrusions. IDC's research shows that roughly one in three MDR customers globally still lack dark web monitoring as part of their service, which represents a significant visibility gap at a time when pre-compromise intelligence is increasingly what separates early detection from late discovery. Providers that integrate dark web monitoring with analyst-triaged intelligence and actionable takedown capability, rather than delivering raw feed data, are closing that gap in a way that directly improves security outcomes for their customers." Yogesh Shivhare, Sr. Research Manager, Security and Trust at IDC.

Built for Microsoft-Centric Security Operations

Built for Ontinue's Microsoft-first security operations model, ION for Dark Web Monitoring helps organizations extend visibility beyond their environment without adding another technology platform. Findings, investigations, and response activities become part of a unified security operations workflow, reducing operational complexity while strengthening overall resilience.

ION for Dark Web Monitoring is available immediately as an add-on service for ION MXDR customers.

For more information about Ontinue, visit our Dark Web Monitoring page.

Additional Resource:

- Blog: Beyond the Perimeter: What Security Teams Are Missing

- Webinar: Ontinue Offers new Dark Web Monitoring service for ION MXDR Customers

About Ontinue

As a leading provider of AI-powered managed security operations, Ontinue is on a mission to give every organization the freedom to focus on what they do best; by making nonstop security excellence accessible, not just aspirational. By combining advanced AI with deep human expertise, Ontinue delivers managed security operations that are tailored to each organization's unique environment, operational needs, and risk profile.

Ontinue's ION SecOps Platform integrates AI-driven insights, automation, and real-time collaboration to continuously prevent, detect, and respond to threats. With deep expertise in Microsoft security technologies, Ontinue helps customers maximize the value of their existing investments while achieving stronger, more scalable security outcomes.

Continuous protection. AI-powered Nonstop SecOps. That's Ontinue.

Media Contact

Alison Raymond

araymond@icrinc.com

SOURCE Ontinue

Share this article

Longer-Term Capex Outlook Remains Muted as Investment Shifts from Coverage to Capacity

REDWOOD CITY, Calif., Oct. 6, 2026 /PRNewswire/ -- According to a recently published report from Dell'Oro Group, a trusted source for market information on the telecommunications, security, networks, and data center industries, worldwide telecom capex increased about 5 percent year-over-year (Y/Y) in the first half of 2026. The stronger-than-expected start to the year follows several years of declining investment and marks an improvement relative to expectations at the beginning of 2026.

Telecom equipment trends remain closely aligned with capex. Aggregate manufacturer revenues across the six telecom equipment programs tracked by Dell'Oro Group—Broadband Access, Microwave & Optical Transport, Mobile Core Network (MCN), Radio Access Network (RAN), and High End Router & Aggregation—also increased approximately 5 percent Y/Y in 1H26.

"The first half was stronger than we expected, but the improving near-term trajectory does not materially change the longer-term capex story," said Stefan Pongratz, Vice President at Dell'Oro Group. "Operators are in a stronger capacity position following the 5G and fiber investment cycles, and the focus is gradually shifting from coverage toward capacity, modernization, automation, and efficiency. At the same time, improving operator revenues are helping to reduce capital intensity ratios even as network investments remain flat."

Additional highlights from the September 2026 Telecom Capex report:

- Despite the stronger start to 2026, Dell'Oro Group made only negligible revisions to its longer-term forecast. Worldwide telecom capex is projected to grow at a 0 to 1 percent CAGR between 2025 and 2030, reflecting a more mature investment environment following the major 5G and fiber coverage cycles.

- Capital intensity, which peaked at 18 percent in 2022, is projected to decline to around 14 percent in 2028, before increasing modestly as early 6G investment emerges.

- Telecom equipment revenues are projected to grow at a 2 to 3 percent CAGR between 2025 and 2030, outpacing CSP capex, partly reflecting incremental demand from cloud providers.

About the Report

The Dell'Oro Group Telecom Capex Report provides in-depth coverage of more than 50 telecom operators, highlighting carrier revenue, capital expenditure, and capital intensity trends. The report provides actual and 5-year forecast details by carrier, by region, by country (United States, Canada, China, India, Japan, and South Korea), and by technology (wireless/wireline). To purchase this report, please contact us by email at [email protected].

About Dell'Oro Group

Dell'Oro Group is a market research firm specializing in strategic competitive analysis of the telecommunications, enterprise networks & security, and data center infrastructure markets. Our firm provides in-depth quantitative data and qualitative analysis to facilitate critical, fact-based business decisions. For more information, please contact Dell'Oro Group at +1.650.622.9400 or visit www.delloro.com.

SOURCE Dell'Oro Group

Share this article

The new IRS-authorized 941 eFile add-on for ezAccounting supercharges quarterly tax filing for businesses, HR teams, and accountants.

REDMOND, Wash., Oct. 6, 2026 /PRNewswire/ -- Halfpricesoft.com has released the updated ezAccounting 2026, fully prepared for the upcoming Q3 Form 941 filing deadline on November 2, 2026. The upgraded accounting and payroll software includes an IRS-authorized eFile service designed to take the stress out of quarterly tax reporting.

Don't delay, start today by downloading ezAccounting for up to 30 days with no registration required and absolutely no obligation.

"The latest ezAccounting 2026 software includes a highly anticipated eFile add-on service directly connected to the IRS," said Dr. Ge, Founder of Halfpricesoft.com. "Our goal is to make payroll and tax compliance as seamless and cost-effective as possible for small businesses."

Key Features of ezAccounting 2026:

- IRS-Authorized eFile: Securely eFile Forms 941, 940, and 94x directly through the interface.

- Complete Payroll Processing: Calculate payroll, print checks, and generate employee tax forms (940, 941, 943, W-2, and W-3).

- Business Management Tools: Track income and expenses, generate custom sales and payroll reports, and manage financial data.

- Multi-Company Support: Manage multiple companies within a single installation at no extra charge.

- Windows Compatibility: Runs on Windows 11, 10, 8, 7, and server environments (network access available).

Try Before You Buy

New customers can download the full version of ezAccounting 2026 with no cost or obligation. This allows business owners and accountants to explore the intuitive graphical interface and test all features, without entering manual data.

Pricing and Availability

ezAccounting 2026 is available for $199.00 per calendar year per single-user license. Optional eFile submissions start at $5.95 per form, scaling down with higher volumes.

Take Control of Payroll and 941 Tax Filing

Download the no cost 30-day trial for ezAccounting 2026 today.

- Download Free Trial: Halfpricesoft.com ezAccounting Download

- Purchase Software License: Buy ezAccounting 2026 ($199)

- Learn More About eFile: ezAccounting eFile Documentation

About Halfpricesoft.com

Halfpricesoft.com is a leading provider of small to midsize business software, including online and desktop payroll software, online employee attendance tracking software, accounting software, in-house business and personal check printing software, W2, software, 1099 software, 1095 ACA form software and ezACH direct deposit software. Software from halfpricesoft.com is trusted by thousands of businesses for over 20 years and will help US businesses simplify payroll processing and streamline business management.

SOURCE Halfpricesoft.com

Share this article

The new lab more than triples the site's existing microbiology testing space, supporting improved laboratory workflow and providing additional capacity to accommodate future growth. The added space features three new biosafety cabinets, allowing PPS to run concurrent tests and reduce sample queue times. All incubators have also been consolidated within the new lab, further streamlining workflow and improving monitoring and accessibility across testing activities.

A key element of the lab is a dedicated sterility testing suite with a Grade C background environment, representing a major upgrade from the previously non-classified area. At its center is a fully integrated, Grade A sterility testing isolator that doubles the site's sterility testing capacity and allows multiple samples to be processed simultaneously. By supporting both open and closed filtration methods, the new isolator provides greater flexibility to meet a wider range of product testing requirements. The area also includes built-in pass-throughs to move samples directly from the manufacturing floor to the lab, reducing contamination risk and protecting product integrity.

These enhancements are expected to reduce testing times by up to 50%, accelerating batch releases, minimizing bottlenecks, and smoothing transitions as programs move from clinical to commercial stages. The new infrastructure also reinforces the site's contamination control and sterility assurance capabilities, while the added capacity reduces supply risk and prepares the site for commercial-scale demand. 

"The new microbiology laboratory represents an important milestone in our Lexington expansion journey," said Nathan Richardson, VP and Site Head, Piramal Pharma Solutions Lexington. "By enhancing sterility testing and microbiological quality capabilities, we are further strengthening our ability to support clients with high quality, reliable, and responsive services throughout the product life cycle. This investment reflects our continued commitment to operational excellence, patient safety, and the future growth of sterile injectable manufacturing in Lexington."

The new microbiology lab solidifies PPS' position as a leader in sterile injectables, empowering Lexington to deliver high quality, reliable, and patient-focused services to small molecule, bioconjugate, and peptide modality clients worldwide.

About Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited.

For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X

About Piramal Pharma Limited

Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.

For more information, visit: Piramal Pharma | LinkedIn

Share this article

Techman Robot strengthens cybersecurity for trusted Physical AI deployment

Techman Robot becomes the world's first built-in vision AI cobot manufacturer to obtain IEC 62443-4-2 SL2 certification

TAIPEI, Oct. 6, 2026 /PRNewswire/ -- Techman Robot has obtained IEC 62443-4-2 Security Level 2 (SL2) cybersecurity certification for its TM AI Cobot S Series following an independent assessment by DEKRA. The milestone strengthens the cybersecurity foundation for deploying collaborative robots in connected manufacturing environments.

As Physical AI moves into production, robots increasingly connect with equipment, manufacturing systems and data infrastructure. Manufacturers need both intelligent automation and confidence in the cybersecurity capabilities of the products they deploy.

Techman Robot integrates built-in vision, artificial intelligence and robotic execution through its SEE • THINK • ACT approach. Independently verified cybersecurity capabilities provide a foundation for trusted deployment.

IEC 62443-4-2 specifies security requirements for industrial automation and control system components. The certification gives manufacturers and system integrators an independently verified reference for assessing the product cybersecurity capabilities of the TM AI Cobot S Series.

Scott Huang, Chief Operating Officer of Techman Robot, said:

"As Physical AI enters production, customers care about more than how intelligent a robot is. They need to know whether it can operate safely and reliably alongside their manufacturing environment over the long term. SEE • THINK • ACT is central to Techman Robot's AI robotics approach, and trusted deployment is a foundation for putting that intelligence to work on the factory floor. The IEC 62443-4-2 SL2 certification reflects our continued efforts to integrate intelligence, cybersecurity and practical manufacturing needs into product development."

Beyond certification, TM AI Cobot has established product lifecycle cybersecurity mechanisms covering vulnerability management, incident reporting and security updates. Techman Robot continues to strengthen these mechanisms in line with the requirements of the European Union's Cyber Resilience Act (CRA).

From built-in vision to built-in AI, Techman Robot remains focused on bringing intelligence into real manufacturing environments with a trusted foundation for deployment.

Share this article

Qurin® launches Qatra™ gDNA extraction kit for large-volume urine processing

- New Research Use Only kit combines proprietary bead surface chemistry and magnetic bead retrieval to enable streamlined genomic DNA extraction from large urine volumes.

- Processing larger volumes (up to 400 mL) may lead to a 7.6-fold increased total DNA yield compared to conventional 40-50 mL volumes.

LEIDEN, Netherlands, Oct. 6, 2026 /PRNewswire/ -- Qurin®, a research and development company focused on urine-based liquid biopsy diagnostics in oncology, announces the launch of the QatraTM Genomic DNA Extraction Lab Kit (RUO), developed specifically for the extraction of genomic DNA (gDNA) from large volumes of urine.

Qatra enables researchers to process urine volumes ranging from standard laboratory samples (40-50 mL) up to a full void (400 mL), providing access to more of the biological material available within the original sample. At the core of the technology is Qurin's proprietary magnetic bead surface chemistry (patent pending), designed for efficient DNA capture from whole urine, combined with a proprietary magnetic retrieval system (patent pending) optimized for recovering DNA-loaded beads directly from large sample volumes. Qatra processes the sample in a single streamlined workflow, reducing sample handling and hands-on processing, while preserving the integrity of the recovered genomic DNA. This is an advantage over current workflows that require large urine samples to be concentrated or divided across multiple extractions. The workflow has also been developed with automation in mind, supporting scalable processing of large-volume urine samples.

In internal studies, Qatra demonstrated greater DNA recovery, with average yields rising 7.6-fold as sample volume increased from 50 to 400 mL. These findings demonstrate the potential of large-volume processing to recover more of the DNA present in a urine sample, particularly when biomarkers are present at low concentrations and analysing only a small aliquot may leave a substantial proportion of the available biomarker material unused.

Qatra R&D Program

The Qatra Genomic DNA Extraction Lab Kit (RUO) is the first product to emerge from Qurin's broader Qatra R&D Program, which is dedicated to developing technologies for the capture and extraction of biomarkers from urine.

Urine is an attractive matrix for molecular research because it can be collected non-invasively and repeatedly and is naturally available in relatively large volumes. Its potential may also extend beyond cancers of the urogenital tract, as small fragments of circulating cell-free DNA, including tumour-derived DNA, can cross the renal filtration barrier and enter urine. At the same time, DNA and other biomarkers can occur at low concentrations, creating a need for technologies capable of efficiently accessing biomarker material from the available urine volume.

The broader Qatra R&D Program is therefore being developed as a modular platform for laboratory and at-home biomarker extraction from urine. The platform is designed to enable high-quality biomarker extraction from volumes up to 400 mL (an average full void) while supporting automated processing. Its modular approach is envisioned to accommodate different biomarker classes, including genomic DNA, cell-free DNA, RNA, extracellular vesicles, proteins and other, using bead-based modules for laboratory workflows and cartridge-based modules for at-home collection and biomarker capture.

"Urine has tremendous potential for molecular analysis, but we need technologies designed around the unique characteristics of the sample," said Marc Peeters, CEO at Qurin. "With Qatra, our aim is simple: process more of the available urine, recover more of its molecular information, and make that process as efficient and scalable as possible."

The Qatra genomic DNA Extraction Lab Kit is available for Research Use Only (RUO) and is not intended for use in diagnostic procedures.

About Qurin

Qurin is a research and development company focused on urine-based liquid biopsy diagnostics in oncology, building an end-to-end platform that connects biomarker extraction with clinically actionable assays. Its two complementary R&D programs address both sides of this approach: the Qatra R&D Program develops technologies to efficiently capture and extract high-quality biomarkers, including DNA, RNA and proteins, from urine volumes up to 400 mL (an average full void), while the QumbraTM R&D Program develops assays and interpretive software that translate urinary biomarker signals into clinically meaningful insights. Together, the programs aim to unlock the potential of urine across the oncology care pathway. For more information, visit www.qurin.com.

SOURCE Qurin

Share this article